Trials / Terminated
TerminatedNCT04721535
A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
A Randomized Double-blinded Controlled Clinical Trial of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DWJ1248 | Orally, 1 tablet of DWJ1248 TID, up to 14 days |
| DRUG | Placebo | Orally, 1 tablet of placebo TID, up to 14 days |
Timeline
- Start date
- 2021-06-07
- Primary completion
- 2021-09-23
- Completion
- 2021-10-06
- First posted
- 2021-01-22
- Last updated
- 2022-12-07
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04721535. Inclusion in this directory is not an endorsement.